CN104955843B - 治疗杜兴氏肌营养不良的抗flt-1抗体 - Google Patents

治疗杜兴氏肌营养不良的抗flt-1抗体 Download PDF

Info

Publication number
CN104955843B
CN104955843B CN201480003714.6A CN201480003714A CN104955843B CN 104955843 B CN104955843 B CN 104955843B CN 201480003714 A CN201480003714 A CN 201480003714A CN 104955843 B CN104955843 B CN 104955843B
Authority
CN
China
Prior art keywords
flt
antibody
muscle
monoclonal antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480003714.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104955843A (zh
Inventor
S·约西亚
T·M·卢比
A·朝仓
D·基夫
L·查纳斯
M·维马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
University of Minnesota System
Original Assignee
Shire Human Genetics Therapies Inc
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetics Therapies Inc, University of Minnesota System filed Critical Shire Human Genetics Therapies Inc
Publication of CN104955843A publication Critical patent/CN104955843A/zh
Application granted granted Critical
Publication of CN104955843B publication Critical patent/CN104955843B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480003714.6A 2013-01-28 2014-01-28 治疗杜兴氏肌营养不良的抗flt-1抗体 Active CN104955843B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757571P 2013-01-28 2013-01-28
US61/757,571 2013-01-28
PCT/US2014/013402 WO2014117160A1 (en) 2013-01-28 2014-01-28 Anti-flt-1 antibodies in treating duchenne muscular dystrophy

Publications (2)

Publication Number Publication Date
CN104955843A CN104955843A (zh) 2015-09-30
CN104955843B true CN104955843B (zh) 2019-08-13

Family

ID=50073518

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480003714.6A Active CN104955843B (zh) 2013-01-28 2014-01-28 治疗杜兴氏肌营养不良的抗flt-1抗体

Country Status (14)

Country Link
US (3) US9957324B2 (enExample)
EP (1) EP2948476B1 (enExample)
JP (2) JP6469022B2 (enExample)
KR (1) KR102259255B1 (enExample)
CN (1) CN104955843B (enExample)
AU (1) AU2014209012B2 (enExample)
BR (1) BR112015017242B1 (enExample)
CA (1) CA2898998C (enExample)
EA (1) EA037501B1 (enExample)
ES (1) ES2676406T3 (enExample)
HK (1) HK1213918A1 (enExample)
IL (1) IL238588B (enExample)
MX (1) MX360153B (enExample)
WO (1) WO2014117160A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2948164B1 (en) 2013-01-28 2019-04-10 Shire Human Genetic Therapies, Inc. Placenta growth factor in treating duchenne muscular dystrophy
MA41899A (fr) * 2015-04-07 2018-02-13 Shire Human Genetic Therapies Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne
US10738123B2 (en) 2015-04-07 2020-08-11 Shire Human Genetic Therapies, Inc. Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia
CA2981961A1 (en) * 2015-04-07 2016-10-13 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
KR102019048B1 (ko) 2017-02-06 2019-09-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 근육긴장저하 치료제 스크리닝 방법
KR101886788B1 (ko) 2017-02-07 2018-08-09 가톨릭대학교 산학협력단 MG53과 Orai1의 결합을 이용한 뒤시엔느 골격근 위축증 치료제 스크리닝 방법
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
WO2023182657A1 (ko) 2022-03-24 2023-09-28 주식회사 케이에스비튜젠 항-fetuin-b 항체 및 해당 항체를 유효 성분으로 포함하는 근육질환의 예방, 치료 또는 개선용 조성물
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055809A2 (en) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055809A2 (en) * 2004-11-18 2006-05-26 Imclone Systems Incorporated Antibodies against vascular endothelial growth factor receptor-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《Anti-Vascular Endothelial Growth Factor Receptor-1Antagonist》;Yan Wu等;《Clinical Cancer Research》;20061101;第12卷(第12期);摘要，第6576页倒数第二段，第6580页倒数第二段 *
《Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice》;Verma M. 等;《Human Molecular Genetics》;20100812;第19卷(第21期);摘要 *
Verma M. 等.《Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice》.《Human Molecular Genetics》.2010,第19卷(第21期), *
Yan Wu 等.《Anti-Vascular Endothelial Growth Factor Receptor-1Antagonist》.《Clinical Cancer Research》.2006,第12卷(第21期), *

Also Published As

Publication number Publication date
IL238588B (en) 2020-04-30
CA2898998C (en) 2023-02-14
EP2948476B1 (en) 2018-06-06
AU2014209012B2 (en) 2018-11-08
EA037501B1 (ru) 2021-04-05
EA201590720A1 (ru) 2015-11-30
EP2948476A1 (en) 2015-12-02
WO2014117160A1 (en) 2014-07-31
ES2676406T3 (es) 2018-07-19
HK1217710A1 (en) 2017-01-20
JP6469022B2 (ja) 2019-02-13
IL238588A0 (en) 2015-06-30
US20150361174A1 (en) 2015-12-17
BR112015017242B1 (pt) 2023-11-07
BR112015017242A2 (enExample) 2017-08-15
JP2019023230A (ja) 2019-02-14
US20180312593A1 (en) 2018-11-01
EA201590720A8 (ru) 2018-09-28
AU2014209012A1 (en) 2015-05-21
JP2016511234A (ja) 2016-04-14
CN104955843A (zh) 2015-09-30
KR20150109386A (ko) 2015-10-01
US9957324B2 (en) 2018-05-01
US20210163603A1 (en) 2021-06-03
KR102259255B1 (ko) 2021-05-31
MX2015009690A (es) 2016-03-31
CA2898998A1 (en) 2014-07-31
MX360153B (es) 2018-10-24
HK1213918A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
US20210163603A1 (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
CN104902915B (zh) 治疗杜兴氏肌营养不良的卵泡抑素
US12435146B2 (en) Anti-Flt-1 antibodies for treating Duchenne muscular dystrophy
CN110914294A (zh) 重组卵泡抑素-fc融合蛋白及其在治疗杜氏肌营养不良中的用途
EP3423479A2 (en) Recombinant follistatin-fc fusion proteins and use in treating duchenne muscular dystrophy
EP3586867A2 (en) Placenta growth factor in treating duchenne muscular dystrophy
HK1217710B (en) Anti-flt-1 antibodies in treating duchenne muscular dystrophy
CA2981954C (en) Anti-flt-1 antibodies for treating duchenne muscular dystrophy
BR122024023570A2 (pt) Polinucleotídeo que codifica um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno, composição farmacêutica, usos relacionados, vetor de expressão, célula isolada e anticorpos anti-flt-1 ou seu fragmento de ligação ao antígeno

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213918

Country of ref document: HK

CB03 Change of inventor or designer information

Inventor after: S.Josiah

Inventor after: T*M*Rupee

Inventor after: A.Asakura

Inventor after: D.Keef

Inventor after: L.Chanas

Inventor after: M. Vic

Inventor before: S.Josiah

Inventor before: T*M*Rupee

Inventor before: A.Asakura

Inventor before: D.Keef

Inventor before: L.Chanas

CB03 Change of inventor or designer information
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20211009

Address after: Osaka, Japan

Patentee after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Patentee after: REGENTS OF THE University OF MINNESOTA

Address before: Massachusetts, USA

Patentee before: SHIRE HUMAN GENETIC THERAPIES, Inc.

Patentee before: REGENTS OF THE University OF MINNESOTA

TR01 Transfer of patent right